So we did not have a bad day yesterday, although that only really is true if you look at the absolute performance and not the relative performance. That being said it was still better than what we have seen recently. We are set for a green start to the day and have some positive news […]
April 5th Biotech Update
While it is possible that this week is decision week for the sector, I am not convinced that it has to be. There is room above and below for it to tread water and not signal its next big move. I see the $150 and $125 levels as the key ones to watch and the […]
February 15 Biotech Update
We have some additional news yesterday but nothing that is necessarily positive for the sector. It certainly rallied in the afternoon and I suspect there is enough juice left for that to continue. Of course, we are only one tweet away from a pullback but I guess that is true of every sector and stock. […]
February 8 Biotech Update
Certainly some news for the sector and not great news but it seems to be having limited impact on the broader sector. In other words, people seem to be seeing GILD problems as isolated to GILD and not the broader sector but that is certainly something we need to watch. 1. I am very glad […]
December 20 Biotech Update
Well, this has been a strangely interesting day for the week before Christmas. I thought the bulk of news was done but I clearly spoke too soon. There is some good news for the sector as well as some good-well-maybe-bad-let-us-argue news. I am going to go through these as sort of quick hits as none […]
August 9 Biotech Update
We certainly have seen some recent under-performance by the sector but given recent strength and run of bad news (trial failures, secondaries, and so on) this is not stunning. So I do not read anything meaningful into this weakness as long as we maintain a higher low and given the recent price action that would […]
March 30 Biotech Update
I am very surprised with the way yesterday turned out. Shrugging off the news to turn positive was impressive even if the sector underperformed the broader market. It seems to support my base case that we are in a bottoming process but also one that will not lead to the sector returning to leadership. We […]
March 28 Biotech Update
We start the week with some biotech news although not the M&A that many expect. I will be interested to see how MDVN trades given its takeover speculation at the end of last week. In any case, we got real news and for the most part it is positive, so the key now is for […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
March 11 Biotech Update
So the sector clearly ended up outperforming yesterday despite a beat down in the broader markets. That being said I still see the large caps as the real laggards in the sector and that seems to be continuing into today. As I noted before, I do not see that as a positive as it looks […]
May 15 2013 – End Of Day Biotech Wrap-up
Well, this is my first daily rundown for subscribers and while many of you have received these as emails, this might be new for others. In general, I like to take some of the more interesting stories of the day and put them into a context that would allow you to develop an effective trading […]
Some highlights from Day 1 at Needham
The 12th Annual Needham Healthcare Conference began today with a number of presentations by widely biotech companies. Below we have a slideshow of the summary slides from companies that we are following or have an interest in. These include Astex (ASTX), Cubist (CBST), Infinity (INFI), Insmed (INSM), ISIS (ISIS), Sarepta (SRPT) and several others.
ACAD – The Last Run to The Parkinson’s Disease Psychosis Results
ACADIA Pharmaceuticals Inc. (ACAD) -NasdaqGM Catalyst: late Nov. P-III results for Parkinson disease Acadia reported a 100% patient enrollment on Sep 05th: ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis Top-Line Data Expected in November 2012, as I mentioned earlier in my last report and since 09/07 the […]
